Carbapenems in clinical practice: A guide to their use in serious infection

International Journal of Antimicrobial Agents

Volumn 11, Issue 2, 1999, Pages 93-100

  Bradley, J S ^e   Garau, J ^a   Lode, H ^b   Rolston, K V I ^e   Wilson, S E ^c   Quinn, J P ^d  

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e NONE

Author keywords

Lactamase; Bacterial infection; Carbapenem

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; MEROPENEM; TOBRAMYCIN;

ABDOMINAL INFECTION; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTER CLOACAE; FEBRILE NEUTROPENIA; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INFECTION; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; MENINGITIS; PERITONITIS; PNEUMONIA; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SEPSIS; URINARY TRACT INFECTION;

BACTERIAL INFECTIONS; CARBAPENEMS; CHILD; DRUG RESISTANCE, MICROBIAL; FEVER; HUMANS; INTENSIVE CARE UNITS; MENINGITIS, BACTERIAL; NEUTROPENIA; PERITONITIS; PNEUMONIA;

EID: 0032966624     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(98)00094-6     Document Type: Review

References (50)

1. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36 Suppl A:1-17.
2. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996;38:409-24.
3. Jarlier V, Fosse T, Philippon A. Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study). Intensive Care Med 1996;22:1057-65.
4. Garau J, Blanquer J, Cobo L, et al. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections. Eur J Clin Microbiol Infect Dis 1997;16:789-96.
5. Buirma RJ, Horrevorts AM, Wagenvoort JH. Incidence of multi-resistant gram-negative isolates in eight Dutch hospitals: The 1990 Dutch Surveillance Study. Scand J Infect Dis Suppl 1991;78:35-44.
6. Verbist L. Incidence of multi-resistance in gram-negative bacterial isolates from intensive care units in Belgium: a surveillance study. Scand J Infect Dis Suppl 1991;78:45-53.
7. Snydman DR. Clinical implications of multi-drug resistance in the intensive care unit. Scand J Infect Dis Suppl 1991;78:54-63.
8. Lopez-Yeste M, Xercavins M, Lite J, Cuchi E, Garau J. Fluoroquinolone and aminoglycoside resistance in chromosomal cephalosporinase-overproducing Gram-negative bacilli strains with inducible β-lactamase. Enferm Infec Microbiol Clin 1996;14:211-4.
9. Livermore DM. β-lactamase-mediated resistance and opportunities for its control. J Antimicrob Chemother 1998;41 Suppl D:25-41.
10. Quinn JP, Studemeister AE, DiVincenzo CA, Lerner SA. Resistance to imipenem in Pseudomonas aeruginosa: clinical experience and biochemical mechanisms. Rev Infect Dis 1988;10:892-8.
11. Colardyn F, Faulkner KL, The meropenem serious infection study group: intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalised patients. J Antimicrob Chemother 1996;38:523-537.
12. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit: ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996;22:387-94.
13. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
14. Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections: multivariate analysis on 604 patients. Arch Surg 1996;131:641-5.
15. Wilson SE, Faulkner K. Impact of anatomical site on bacteriological and clinical outcome in the management of intra-abdominal infections. Am Surg 1998;64:402-7.
16. Bohnen JM, Mustard RA, Oxholm SE, Schouten BD. APACHE II score and abdominal sepsis: a prospective study. Arch Surg 1988;123:225-9.
17. Hopkins JA, Lee JCH, Wilson SE. Susceptibility of intra-abdominal isolates at operation: a predictor of postoperative infection. Am Surg 1993;59:791-6.
18. Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M, The Canadian Intra-abdominal Infection Study Group. Management of intra-abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. Arch Surg 1996;131:1193-1201.
19. Huizinga WK, Warren BL, Baker LW et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995;36 Suppl A:179-189.
20. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995;21:544-50.
21. Berne TV, Yellin AE, Appleman MD, Heseltine PN, Gill MA. Meropenem versus tobramycin with clindamycin in the antibiotic management of patients with advanced appendicitis. J Am Coll Surg 1996;182:403-7.
22. Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections. Am J Surg 1997;174:284-90.
23. Kanellakopoulou K, Giamarellou H, Papadothomakos et al. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993;12:449-453.
24. Brismar B, Malmborg AS, Tunevall G, et al. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections. J Antimicrob Chemother 1995;35:139-48.
25. Geroulanos SJ. Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery: Meropenem Study Group. J Antimicrob Chemother 1995;36:191-205.
26. Hemsell DL, Martens MG, Faro S, Gall S, McGregor JA. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Clin Infect Dis 1997;24 Suppl 2:S222-S230.
27. Nichols RL, Smith JW, Geckler RW, Wilson SE. Meropenem versus imipenem/cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 1995;88:397-404.
28. Hopkins JA, Wilson SE, Bobey DG. Adjunctive antimicrobial therapy for complicated appendicitis:bacterial overkill by combination therapy. World J Surg 1994;18:933-8.
29. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis - relation between bacteriologic etiology and lung function. Chest 1998;113:1542-8.
30. Finch RG, Pemberton K, Gildon KM. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime. J Chemother 1998;10:35-46.
31. Harnacher J, Vogell F, Lichey J, et al. Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients-a comparison of meropenem and imipenem/cilastatin: COPD Study Group. J Antimicrob Chemother 1995;36 (Suppl A):121-133.
32. Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin:a randomized study: Meropenem Lower Respiratory Infection Group. Crit Care Med 1997;25:1663-70.
33. American Thoracic Society. Hospital-acquired pneumonia in adults:diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. Am J Respir Crit Care 1996;153:1711-1725.
34. Bradley JS. Selecting therapy for serious infections in children: maximizing safety and efficacy. Diagn Microbiol Infect Dis 1998;31:405-10.
35. Rodriguez W, Bradley JS, Odio C. Meropenem vs cefotaxime in the treatment of pediatric meningitis. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Canada) 1997. Washington DC: American Society for Microbiology (abstract LM-002).
36. Klugman KP, Dagan R, The Meropenem Meningitis Study Group. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrob Agents Chemother 1995;39:1140-1146.
37. Wong VK, Wright HT Jr, Ross LA, et al. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-5.
38. Bradley JS, Scheld WM. The challenge of penicillin-resistant Streptococcus pneumoniae meningitis: current antibiotic therapy in the 1990s. Clin Infect Dis 1997;24 Suppl 2:S213-S221.
39. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
40. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis 1997;25:551-573.
41. Rolston KVI, Bodey GP. Infections in patients with cancer. In: Holland JF, Frei E III , Bast RC Jr, Kufe DW, Morton DL, Weichfelbaum RR, ed. Cancer Medicine, 3rd ed. Baltimore: Williams and Wilkins, 1997:2416-2441.
42. Cometta A, Glauser MP. Empiric antibiotic monotherapy with carbapenems in febrile neutropenia: a review. J Chemother 1996;8:375-81.
43. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621-9.
44. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-5.
45. Winston DJ, Ho WG, Bruckner DA, Champlin E. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 1991;115:849-59.
46. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-76.
47. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
48. Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185-200.
49. Mason B, Gildon KM, Bell JM, Megson GM. Meropenem in the empirical management of febrile neutropenia. Abstract no. 40 presented at the Third International Symposium on Febrile Neutropenia, December 10-13 1997.
50. Rolston KV. Expanding the options for risk-based therapy in febrile neutropenia. Diagn Microbiol Infect Dis 1998;31:411-6.